Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

Xilio plans to bring its two lead immuno-oncology candidates to clinical proof-of-concept data, as well as advance its earlier stage programs, with a tranched $100.5 million series B.

Takeda Ventures Inc. led

Read the full 313 word article

How to gain access

Continue reading with a
two-week free trial.